revefenacin revefenacin revefenacin, sold under the brand name yupelri, is a medication for the treatment of chronic obstructive pulmonary disease (copd). it was approved for use in the united states in 2018. it was developed by theravance biopharma and is marketed by mylan. revefenacin is formulated as a solution that is nebulized and inhaled. revefenacinclinical datatrade namesyupelriahfs/drugs.commonographmedlineplusa619009license data us dailymed: revefenacin routes ofadministrationinhalationatc coder03bb08 (who) legal statuslegal status us: ℞-only identifierscas number864750-70-9pubchem cid11753673drugbankdb11855chemspider9928376uniig2ae2ve07okeggd10978chemical and physical dataformulac35h43n5o4molar mass597.760 g·mol−13d model (jsmol)interactive image smiles cn(ccn1ccc(cc1)oc(=o)nc2=cc=cc=c2c3=cc=cc=c3)c(=o)c4=cc=c(c=c4)cn5ccc(cc5)c(=o)n inchi inchi=1s/c35h43n5o4/c1-38(34(42)29-13-11-26(12-14-29)25-40-19-15-28(16-20-40)33(36)41)23-24-39-21-17-30(18-22-39)44-35(43)37-32-10-6-5-9-31(32)27-7-3-2-4-8-27/h2-14,28,30h,15-25h2,1h3,(h2,36,41)(h,37,43)key:fydwdcifzsgnbu-uhfffaoysa-n revefenacin is a bronchodilator that exerts its effect as a long-acting muscarinic antagonist.